Actuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest first-time offering this year, but it wasn’t far off – only three other drug developers had smaller IPOs, including the 14th biopharma firm to go public in 2024, OS Therapies Incorporated, which grossed $6.4m from the sale of 1.6m shares at $4 each on 31 July.
Finance Watch: Actuate Launches 15th Biopharma IPO In The US For 2024
Funding Comes Ahead Of Q1 Phase II Readout
Public Company Edition: Actuate Therapeutics grossed $22.4m in its first-time offering, while already-public companies recently tapped a variety of sources for funding. Arrowhead negotiated a credit facility for up to $500m and ANI sold $275m worth of notes, among other financings.
